Skip to main content

Peer Review reports

From: Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France

Original Submission
27 Apr 2018 Submitted Original manuscript
30 Jul 2018 Reviewed Reviewer Report - Reviewer 2
29 Sep 2018 Author responded Author comments - Audrey Petitjean
Resubmission - Version 2
29 Sep 2018 Submitted Manuscript version 2
18 Dec 2018 Author responded Author comments - Audrey Petitjean
Resubmission - Version 3
18 Dec 2018 Submitted Manuscript version 3
10 Jan 2019 Author responded Author comments - Audrey Petitjean
Resubmission - Version 4
10 Jan 2019 Submitted Manuscript version 4
28 Jan 2019 Author responded Author comments - Audrey Petitjean
Resubmission - Version 5
28 Jan 2019 Submitted Manuscript version 5
Publishing
31 Jan 2019 Editorially accepted
11 Feb 2019 Article published 10.1186/s12885-019-5335-8

You can find further information about peer review here.

Back to article page